Last reviewed · How we verify
Remifentanil 2 MG
At a glance
| Generic name | Remifentanil 2 MG |
|---|---|
| Also known as | Ultiva 2 mg., Rentanil 2 mg., Opiva 2 mg. |
| Sponsor | Yeditepe University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of Different Drugs for Glottic Atomization on Postoperative Sore Throat After Thyroid Surgery (PHASE4)
- Comparison of Target-Controlled and Manual Total Intravenous Anesthesia in Supratentorial Surgery (NA)
- A Study on Median Effective Concentration of Ciprofol Combined With Remifentanil Via Target-controlled Infusion for Inhibiting Tracheal Intubation Stimulation Under qNOX Index Monitoring (NA)
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- Propofol vs Remifentanil for Sedation in Gastroscopy (NA)
- qCON/qNOX-Guided Anesthesia in Patients Undergoing Thyroidectomy Surgery (NA)
- Sacral Erector Spinae Plane Block in Transurethral Prostate Resection Surgery (NA)
- Opioid-Free vs Opioid-Based Anesthesia in Bariatric Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Remifentanil 2 MG CI brief — competitive landscape report
- Remifentanil 2 MG updates RSS · CI watch RSS
- Yeditepe University portfolio CI